Effects of naltrexone during the descending limb of the blood alcohol curve

American Journal on Addictions

Volumn 17, Issue 4, 2008, Pages 257-264

  Ray, Lara A ^a,b   Hutchison, Kent E ^b   MacKillop, James ^a   Miranda Jr , Robert ^a   Audette, Amy ^b   Swift, Robert ^a,c   Monti, Peter M ^a,c  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c PROVIDENCE VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; NALTREXONE; PLACEBO;

ADULT; ALCOHOL BLOOD LEVEL; ALCOHOL INTOXICATION; ALCOHOLISM; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MALE; MOOD; PROVOCATION TEST; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AFFECT; ALCOHOLIC INTOXICATION; ALCOHOLISM; AROUSAL; DOUBLE-BLIND METHOD; ETHANOL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; QUESTIONNAIRES; SEX FACTORS;

EID: 39749135648     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490802138400     Document Type: Article

References (74)

1. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl). 1998;139:2-19.
2. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology (Berl). 1997;129:99-111.
3. Earleywine M. Confirming the factor structure of the anticipated biphasic alcohol effects scale. Alcohol Clin Exp Res. 1994;18:861-866.
4. Earleywine M. Anticipated biphasic effects of alcohol vary with risk for alcoholism: A preliminary report. Alcohol Clin Exp Res. 1994;18:711-714.
5. Earleywine M, Martin C. Anticipated stimulant and sedative effects of alcohol vary with dosage and limb of the blood alcohol curve. Alcohol Clin Exp Res. 1993;17:135-139.
6. Erblich J, Earleywine M, Erblich B, Bovbjerg DH. Biphasic stimulant and sedative effects of ethanol: Are children of alcoholics really different? Addict Behav. 2003;28:1129-1139.
7. Martin CS, Earleywine M, Musty RE, Perrine MW, Swift RM. Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res. 1993;17:140-146.
8. Lewis MJ, June HL. Neurobehavioral studies of ethanol reward and activation. Alcohol. 1990;7:213-219.
9. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. 1987;94:469-492.
10. Leigh BC. Beliefs about the effects of alcohol on self and others. J Stud Alcohol. 1987;48:467-475.
11. O'Malley S, Maisto S. Factors affecting the perception of intoxication: Dose, tolerance, and setting. Addict Behav. 1984;9:111-120.
12. Balldin J, Berglund M, Borg S, et al. A six-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res. 2003;27:1142-1149.
13. Monti PM, Rohsenow DJ, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and one-year outcomes. Alcohol Clin Exp Res. 2001;25:1634-1647.
14. Rubio G, Manzanares J, Lopez-Munoz F, et al. Naltrexone improves outcome of a controlled drinking program. J Subst Abuse Treat. 2002;23:361-366.
15. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatry. 1999;156:1758-1764.
16. Guardia J, Caso C, Arias F, et al. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: Results from a multicenter clinical trial. Alcohol Clin Exp Res. 2002;26:1381-1387.
17. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92-99.
18. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kouppasalmi K, Sinclair JD. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287-292.
19. Latt NC, Jurd S, Houseman J, Wultzke SE. Naltrexone in alcohol dependence: A randomized controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176:530-534.
20. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876-880.
21. O'Malley SS, Jaffe AJ, Change G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence: A controlled study. Arch Gen Psychiatry. 1992;49:881-887.
22. Chick J, Anton R, Checinski K, et al. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. 2000;35:587-593.
23. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: A randomized controlled trial. Addiction. 2001;96:1565-1573.
24. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence, the COMBINE study: A randomized controlled trial. JAMA. 2006;295:2003-2017.
25. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazedone for treatment of alcohol dependence: A placebo-controlled trial. Neuropsychopharmacology. 2000;22:493-503.
26. Killeen TK, Brady KT, Gold PB, et al. Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res. 2004;28:1710-1717.
27. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med. 2001;345:1734-1739.
28. Anton RF, Drobes DJ, Voronin K, Durazo-Avizu R, Moak D. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking. Psychopharmacology (Berl). 2004;173:32-40.
29. Drobes DJ, Anton RF, Thomas SE, Vornin K. Effects of naltrexone and namefene on subjective response to alcohol among non-treatment seeking alcoholics and social drinkers. Alcohol Clin Exp Res. 2004;28:1362-1370.
30. King AC, Volpicelli JR, Frazer A, O'Brien CP. Effects of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl). 1997;129:15-22.
31. McCaul ME, Wand GS, Stauffer R, Lee SM, Rohde CA. Naltrexone dampens ethanol-induced cardiovascular and hypothalamicpituitary-adrenal axis activation. Neuropsychopharmacology. 2001;25:537-547.
32. Ray LA, Hutchison KE. A double-blind placebo-controlled study of the effects of naltrexone on alcohol sensitivity and genetic moderators of medication response. Arch Gen Psychiatry. 2007;64:1069-1077.
33. Swift RM, Whelihan W, Kusnetsov O, Buongiorno G, Hsuing H. Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatry. 1994;151:1463-1467.
34. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP. Effects of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry. 1995;152:613-615.
35. Davidson D, Palfai T, Bird C, Swift R. Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res. 1999;23:195-203.
36. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl). 2002;160:19-29.
37. McCaul ME, Wand GS, Eissenberg T, Thode CA, Cheskin LJ. Naltrexone alters subjective and psychomotor responses to alcohol in heavy drinking subjects. Neuropsychopharmacology. 2000;22:480-492.
38. de Wit H, Svenson J, York A. Non-specific effect of naltrexone on ethanol consumption in social drinkers. Psychopharmacology (Berl). 1999;146:33-41.
39. Doty P, de Wit H. Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers. Behav Pharmacol. 1995;6:386-394.
40. Doty P, Kirk JM, Cramblett MJ, de Wit H. Behavioral responses to ethanol in light and moderate social drinkers following naltrexone pre-treatment. Drug Alcohol Depend. 1997;47:109-116.
41. Peterson JB, Conrod P, Vassileva J, Gianoulakis C, Pihl RO. Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication. Review of Psychiatric Neuroscience. 2006;31:386-393.
42. Brick J. Standardization of alcohol calculations in research. Alcohol Clin Exp Res. 2006;30:1276-1287.
43. Dunn ME, Earleywine M. Activation of alcohol expectations in memory in relation to limb of the blood alcohol curve. Psychol Addict Behav. 2002;15:18-24.
44. Soderlund H, Parker ES, Schwartz BL, Tulving E. Memory encoding and retrieval on the ascending and descending limbs of the blood alcohol concentration curve. Psychopharmacology (Berl). 2005;182:305-317.
45. Pihl RO, Paylan SS, Gentes-Hawn A, Hoaken PNS. Alcohol affects executive cognitive functioning differentially on the ascending versus descending limb of the blood alcohol concentration curve. Alcohol Clin Exp Res. 2003;27:773-779.
46. Evans SM, Levin FR. Differential response to alcohol in light and moderate female social drinkers. Behav Pharmacol. 2004;15:167-181.
47. Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict. 2001;10:258-268.
48. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T. Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol Alcohol. 2005;40:227-233.
49. Rohsenow DJ, Miranda, R, Mcgeary J, Monti PM. Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol. 2007;15:272-281.
50. Allen JP, Litten RZ, Fertig JB, Babor T. A review of research on the Alcohol Use Disorders Identification Test (AUDIT). Alcohol Clin Exp Res. 1997;21:613-619.
51. Li T, Yin S, Crabb DW, O'Connor S, Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res. 2001;25:136-144.
52. O'Connor S, Morzorati S, Christian J, Li T. Clamping breath alcohol concentration reduces experimental variance: Application to the study of acute tolerance to alcohol and alcohol elimination rate. Alcohol Clin Exp Res. 1998;22:202-210.
53. Ramchandani VA, Bolane J, Li TK, O'Connor S. A physiologically-based pharmacokinetic (PBPK) model for alcohol facilitates rapid BrAC clamping. Alcohol Clin Exp Res. 1999;23:617-623.
54. Ray LA, Hutchison KE. A polymorphism of the mu-opioid receptor gene and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res. 2004;28:1789-1795.
55. Ray LA, Meskew-Stacer S, Hutchison KE. The relationship between prospective self-rating of alcohol sensitivity and craving and experimental results from two alcohol challenge studies. J Stud Alcohol Drugs. 2007;68:379-384.
56. Ray LA, McGeary J, Marshall E, Hutchison KE. Risk factors for alcohol misuse: Integrating heart rate response to alcohol, alcohol sensitivity, and personality factors. Addict Behav. 2006;31:1959-1973.
57. Del Boca FK, Kranzler HR, Brown J, Korner PF. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res. 1996;20:1412-1417.
58. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res. 1995;19:600-606.
59. MacKillop J. Factor structure of the alcohol urge questionnaire under neutral conditions and during a cue-elicited urge state. Alcohol Clin Exp Res. 2006;30:1315-1321.
60. Schuckit MA. Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry. 1984;41:879-884.
61. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. San Diego: Educational & Industrial Testing Service; 1971.
62. Jacobson AF, Goldstein BJ, Dominguez RA, Steinbook RM. Interrater agreement and interclass reliability measure of SAFTEE in psychopharmacologic clinical trials. Psychopharmacol Bull. 1986;22:382-388.
63. Levine J, Schooler N. SAFTEE: A technique for systematic assessment of side effects in clinical trials. Psychopharmacol Bull. 1986;22:343-381.
64. Kaplan R, Hesslebrock V, O'Conner S, DePalma N. Behavioral and EEG responses to alcohol in nonalcoholic men with a family history of alcoholism. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:873-885.
65. Conrod P, Peterson J, Pihl R, Mankowski S. Biphasic effects of alcohol on heart rate are influenced by alcoholic family history and rate of alcohol ingestion. Alcohol Clin Exp Res. 1997;21:140-149.
66. Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293:1617-1625.
67. Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR. Targeted versus daily naltrexone: Secondary analysis of effects on average daily drinking. Alcohol Clin Exp Res. 2006;30:860-865.
68. Pettinati HM, Kampman KM, Lynch KG, et al. Gender differences with high-dose naltrexone in the patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat. 2008; 34:378-390.
69. Bond C, LaForge KS, Tian M, et al. Single-nucleotide polymorphism in the human μ-opioid receptor gene alters β-endorphin binding and activity: Possible implications for opiate addiction. Neurobiology. 1998;95:9608-9613.
70. Herz A. Endogenous opioid systems and alcohol addiction. Psychopharmacology. 1997;129:99-111.
71. Kreek MJ. Opioid receptors: Some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases. Neurochem Res. 1996;21:1469-1488.
72. Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics. Arch Gen Psychiatry. 1998;55:354-360.
73. Grobin AC, Matthews DB, Devaud LL, Morrow AL. The role of GABA(A) receptors in the acute and chronic effects of ethanol. Psychopharmacology. 1998;139:2-19.
74. Buck KJ. Molecular genetic analysis of the role of GABAergic systems in the behavioral and cellular actions of alcohol. Behav Genet. 1996;26:313-323.